SOURCE: PharmaCom BioVet Inc.

August 15, 2008 09:00 ET

PharmaCom BioVet (Previously ABV Gold) Announces the Corporate Philosophy of PharmaCom BioVet Inc. and Future Expansion Approach

RALEIGH, NC--(Marketwire - August 15, 2008) - Gary S. Berthold, President and Chief Executive Officer of PharmaCom BioVet Inc., previously ABV Gold, Inc. (PINKSHEETS: ABVG), would like to take this occasion to announce to shareholders the name change of ABV Gold, Inc. to PharmaCom BioVet Inc. Mr. Berthold would like to take this opportunity to announce a comprehensive synopsis of PharmaCom BioVet Inc. and Future Expansion Approach and comments, "The corporate philosophy of PharmaCom BioVet Inc. (PCBV) is to introduce and further develop Bone Marrow Transplantation and other cancer treatment procedures to benefit companion animals (canine and feline) that are diagnosed with lymphoma, other types of cancers, and other diseases.

"With this in mind, PharmaCom BioVet Inc. has established and incorporated working relationships and partnerships with some of the world's top Veterinary Oncologists and Veterinary Cancer Researchers to enable PharmaCom BioVet to bring innovative new treatment procedures to the companion animal healthcare market."

Mr. Berthold continues, "The human-animal bond is extremely strong and continues to grow as many pet owners consider their pets to be family members. This has created an expanding companion animal care marketplace." In the United States alone, it is estimated that companion animal caregivers spend in excess of $52 billion annually on overall companion animal care.

In the Veterinary Oncology care field it is estimated that the annual dollars spent specifically on cancer diagnostics and treatment is substantial and increasing at a significant rate. This level of therapeutic care is provided primarily by using established human cancer therapeutic products and adapting them for animal use.

There is a remarkable opportunity to develop and introduce effective new products and procedures -- such as Canine Bone Marrow Transplantation -- that PharmaCom BioVet Inc. is introducing into the veterinary marketplace.

PharmaCom BioVet Inc. has begun to establish a facility for the treatment and further development of a Canine Bone Marrow Transplant Center in the Pacific Northwest Region. This center will be the world's first Canine Bone Marrow Transplant Center established to treat canines and felines that are afflicted with lymphoma and other cancers.

PharmaCom BioVet Inc. expects to have a projected income in 2009 of approximately $7,960,000, increased to approximately $9,167,000 in 2010 and a forecasted increase to approximately $11,917,000 for calendar 2011 based upon conservative projections. Forecasted revenues will be derived from a variety of sources with the establishment of PharmaCom BioVet facilities at academic universities throughout the United States and Canada and private veterinary practices on a regionalized basis, thus providing the greatest availability of treatment options to our patients. We are currently in negotiations with several of these locations.

In addition today PharmaCom BioVet Inc. welcomes the newly elected members and Officers of its Board of Directors and future Advisory Board. The Board members are as follows: Ms. Diane D. Dalmy (SEC Attorney) & Director, Mrs. Sharon Berthold (E.V.P Secretary, Treasurer and Director), Mr. Steve A. York (V.P Marketing and Operations/Director), Mr. Dino Paolucci Jr. (Director) Mr. Gary Berthold (President/CEO and Chairman of the Board). The future Advisory Board will consist of: Dr. Jeffrey N. Bryan, Dr. Steven Suter and Dr. William Dernell in addition to other industry specialists.

The Board and Advisory members will help establish PCBV's priorities and drive the initiatives and projects that are undertaken. "This new Board brings a wealth of knowledge and experience that will reinforce PCBV and its ability to support companion animal cancer treatment centers around the country," said Gary Berthold, PCBV President. "The Board will be focused on advancing the Veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country and North America," added Berthold.

To locate additional comprehensive information please visit:

Important Information about Forward-Looking Statements:

All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other events and conditions.

Contact Information